Danny Hart, Vice President, Business Development, focuses on the Company’s investment activity by identifying, evaluating, structuring and completing the Company’s alternative, non-dilutive financing investments (structured debt, synthetic royalty, royalty monetization) for late-stage pharmaceutical, device and diagnostic companies. Additionally, Mr. Hart monitors and restructures, when necessary, PDL’s ongoing financing investments. He joined PDL BioPharma in January 2010 as the Company’s Corporate Counsel. Since joining the Company, Mr. Hart was promoted to Associate General Counsel and Assistant Secretary in April 2011 and then to Deputy General Counsel and Assistant Secretary in January 2012. In September 2014, Danny was elevated to Vice President, Business Development, a non-legal role evaluating and structuring PDL’s investment transactions. From 2006 until he joined the Company Danny worked as an associate with Hogan & Hartson LLP (now Hogan Lovells US LLP), a leading international law firm, where his practice focused on securities, corporate governance and mergers and acquisitions. Before joining Hogan & Hartson Danny began his legal career at Skadden, Arps, Slate, Meagher & Flom LLP, a leading international law firm, where he focused on corporate restructurings. Danny received a J.D. from Vanderbilt University Law School and a B.A. from the University of Washington in Seattle.